Astec LifeSciences Announces Q4 FY26 and FY26 Consolidated Financial Results
Astec LifeSciences Limited announced its consolidated financial results for the fourth quarter and the full year ended March 31, 2026.Q4 FY26 and FY26 Performance Summary
According to the company, the consolidated financial performance showed a notable increase in top-line revenue across both the quarter and the full fiscal year.Q4 FY26 Financial Highlights
The company reported consolidated total income of ₹161.3 crore in Q4 FY26, an increase from ₹120.3 crore reported in Q4 FY25. Consolidated EBITDA for the quarter stood at ₹11.8 crore in Q4 FY26, up significantly from ₹6.3 crore in Q4 FY25. The reported Loss after tax for Q4 FY26 was ₹7.7 crore, compared to a loss of ₹16.1 crore in Q4 FY25.
Full Year FY26 Financial Highlights
For the full fiscal year, Astec reported consolidated total income of ₹453.2 crore in FY26, compared to ₹386.9 crore in FY25. The company recorded a consolidated EBITDA Breakeven of ₹0.5 crore in FY26, moving from an EBITDA loss of ₹60.6 crore in FY25. The reported Loss (after exceptional items and tax) for FY26 was ₹80.9 crore, relative to a loss of ₹134.7 crore in FY25.
The overall financial performance metrics are summarized below:
| Particulars (₹ crore) | Q4FY26 | Q4FY25 | %Change | FY26 | FY25 | %Change |
|---|---|---|---|---|---|---|
| Total Income | 161.3 | 120.3 | 34.0% | 453.2 | 386.9 | 17.1% |
| EBITDA (before Exceptional Items) | 11.8 | 6.3 | 86.9% | 0.5 | (60.6) | NM |
| Profit/(Loss) (before Exceptional Items and Tax) | (7.9) | (15.7) | NM | (78.9) | (141.0) | NM |
| Profit/(Loss) after Exceptional items and Tax | (7.7) | (16.1) | NM | (80.9) | (134.7) | NM |
Note: NM means Not Measurable.
Operational Performance Details
Highlighting the segment performance, the company provided the following breakdowns for revenue from operations:| Category Breakdown | Q4FY26 | Q4FY25 | %Change | FY26 | FY25 | %Change |
|---|---|---|---|---|---|---|
| Enterprise | 69.2 | 50.5 | 37.1% | 213.4 | 177 | 20.6% |
| Contract Manufacturing & New Products | 89.4 | 69 | 29.5% | 234.7 | 204.3 | 14.9% |
Another view of revenue breakdown was provided by geography:
| Geography Breakdown | Q4FY26 | Q4FY25 | %Change | FY26 | FY25 | %Change |
|---|---|---|---|---|---|---|
| Exports | 103.7 | 96 | 8.0% | 277.4 | 259.9 | 6.7% |
| Domestic | 54.9 | 23.5 | 133.8% | 170.7 | 121.4 | 40.6% |
Chairperson’s Commentary
Mr. Vishal Sharma, Chairperson of Astec LifeSciences Limited, commented on the strong revenue growth delivered in Q4 FY26. He stated that the 34% year-over-year revenue growth was primarily attributed to improved volumes in both the Enterprise and Contract Manufacturing segments. The revenue also saw a sequential increase of 29% over Q3 FY26, driven mainly by Enterprise Volumes.Mr. Sharma noted that the improved volumes in the Enterprise and CDMO segments contributed significantly to margin expansion. This led to an increase in EBITDA to ₹11.8 crore in Q4 FY26, marking an 87% year-over-year growth compared to ₹6.3 crore in Q4 FY25.
About Astec LifeSciences Limited
Astec LifeSciences Limited was incorporated in 1994. The company specializes in the manufacturing of agrochemical active ingredients (technical), bulk, formulations, and intermediate products. Astec maintains a healthy sales mix between exports and domestic sales. The company exports to over 18 countries, including the United States and countries across Europe, West Asia, South-East Asia, Latin America, and Africa.ASTEC Stock Price Movement
Today, Astec LifeSciences Limited shares edged higher, rallying 3.88% to close at ₹749.9. The move was supported by robust interest, with 96,049 shares trading in the stock today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: